Cardiovascular health benefits of fish oil

Fish Oil: Production, Consumption and Health Benefits

Volumn , Issue , 2012, Pages 41-71

  Karalis, Dean G ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892796018     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (120)

1. Kris-Etherton PM, Harris WS, Appel LJ; for the Nutrition Committee. AHA Scientific Statement: Fish consumption, fish oil, omega-3 fatty acids and cardiovascular disease. Circulation 2002; 106: 2747-2757.
2. Siri-Tarino PW, Sun Q, Hu FB, Krauss, RM. Saturated fat, carbohydrate, and cardiovascular disease. Am J Clin Nutr 2010; 91: 502-509.
3. Mozzaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willet WC. Trans fatty acids and cardiovascular disease. N Engl J Med 2006; 354: 1601-1613.
4. Kark JD, Kaufmann NA, Binka F, Goldberger N, Berry EM. Adipose tissue n-6 fatty acids and acute myocardial infarction in a population consuming a diet high in polyunsaturated fatty acids. Am J Clin Nutr 2008; 77: 796-802.
5. Lang PD, Degott M, Heuck CC, Opherk D, Vollmar J. Fatty acid composition of adipose tissue, blood, lipids, and glucose tolerance in patients with different degrees of angiographically documented coronary arteriosclerosis. Res Exp Med 1982: 180: 161-168.
6. Sachs FM, Campos H. Polyunsaturated fatty acids, inflammation, and cardiovascular disease: time to widen our view of the mechanisms. J Clin Endocrinol Metab 2006; 91: 398-400.
7. Ferrucci L, Cherubini A, Bandinelli S, Bartali B, Corsi A, Lauretani F, Martin A, Andres-Lacueva C, Senin U, Guralnik JM. Relationship of plasma unsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab 2006; 91: 439-446.
8. Harris WS, Mozaffarian D, Rimm E, Kris-Etherton P, PhD, Rudel LL, Appel LJ, Engler MM, Engler MB, Sacks F. Omega-6 fatty acids and risk for cardiovascular disease. A science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. Circulation 2009; 119: 902-907.
9. Ramsden CE, Hibbeln JR, Majchrzak SF, Davis JM. N-6 fatty acid-specific and mixed polyunsaturated dietary interventions have different effects on CHD risk: a metaanalysis of randomized controlled trials. Br J Nutr 2010; 104: 1586-1600.
10. Harris WS, Poston WC, Haddock CK. Tissue n-3 and n-6 fatty acids and risk for coronary heart disease events. Atherosclerosis 2007; 193: 1-10.
11. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocrine Reviews 2002; 23: 201-229.
12. Mudd JO, Borlaug BA, Johnston PV, Kral BG, Rouf R, Blumenthal RS, Kwiterovich PO. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardiol 2007; 50: 1735-1741.
13. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993; 94: 350-356.
14. Ip S, Lichtenstein AH, Chung M, Lau J, Balk EM. Systemic review: association of lowdensity lipoprotein subfractions with cardiovascular outcomes. Ann Intern Med 2009; 150: 474-484.
15. Greene DJ, Skeggs JW, Morton RE. Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI). J Biol Chem 2001; 276: 4804-4811.
16. Bang HO, Dyerberg J, Nielsen AB. Plasma lipid and lipoprotein pattern in Greenlandic West-Coast Eskimos. Lancet 1971; 1: 1143-1146.
17. Kromann N, Green A. Epidemiologic studies in the Upernavik District, Greenland. Acta Med Scand 1980; 208: 401-406.
18. Iso H, Kobayashi M, Ishihara J, Sasaki S, Okada K, Kita Y, Kokubo Y, Tsugane S for the JPHC Study Group. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation 2006; 113: 195-202.
19. Stone NJ. Fish consumption, fish oil, lipids, and coronary heart disease. Circulation 1996; 94: 2337-2340.
20. Daviglus ML, Stamler J, Orencia AJ, Dyer AR, Liu K, Greenland P, Walsh MK, Morris D, Shekelle RB. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med 1997; 336: 1046-1053.
21. Zhang J, Sasaki S, Amano K, Kesteloot H. Fish consumption and mortality from all causes; ischemic heart disease, and stroke: an ecological study. Prev Med 1999; 28: 520-529.
22. Hu FB, Bronner L, Willett WC, Stampfer MJ, Rexrode KM, Albert CM, Hunter D, Manson JE. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 22001; 287: 1815-1821.
23. Kromhout D, Bloemberg BP, Feskens EJ, Hertog MG, Menotti A, Blackburn H. Alcohol, fish, fibre and antioxidant vitamins intake do not explain population differences in coronary heart disease mortality. Int J Epidemiol 1996; 25: 753-759.
24. Verschuren WH, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F, Karvonen MJ, Nedelijković S, Nissinen P, Toshima H. Serum total cholesterol and long-term coronary heart disease mortality in different cultures: Twenty-five-year follow-up of the seven countries study. JAMA 1995; 274: 131-136.
25. Sekikawa A, Ueshima H, Kadowaki T, El-Saed A, Okamura T, Takamiya T, Kashiwagi A, Edmundowicz D, Murata K, Sutton-Tyrrell K, Maegawa H, Evans RW, Kita Y, Kuller LH, for the ERA JUMP Study Group. Less subclinical atherosclerosis in Japanese men in Japan than in white men in the United States in the post-World War II birth cohort. Am J Epidemiol 2001; 165: 617-624.
26. D'Agostino SR, Grundy S, Sullivan LM, Wilson P, for the CHDRPG. Validation of the Framingham Coronary Heart Disease Prediction Scores: results of a multiple ethnic group investigation. JAMA 2001; 286: 180-187.
27. Sekikawa A, Curb D, Ueshima H, El-Saed A, Kadowaki T, Abbott RD, Evans RW, Rodriguez BL, Okamura T, Sutton-Tyrrell K, Nakamura Y, Masaki K, Edmundowicz D, Kashiwagi A, Willcox BJ, Takamiya T, Mitsunami K, Seto TB, Murata K, White RL, Kuller LH, for the ERA JUMP Study Group. Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American and white men. J Am Coll Cardiol 2008; 52: 417-424.
28. Burr ML, Gilbert JF, Holliday RM, Elwood PC, Fehily AM, Rogers S, Sweetnam PM, Deadman NM. Effects of changes in fat, fish, and fibre intakes on death and myocardial infarction and reinfarction trial (DART). Lancet 1989; 2: 757-761.
29. Singh RM, Mohammad AN, Sharma JP, Kumar R, Rastogi V, Moshiri M. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected myocardial infarction: the Indian experiment of infarct survival-4. Cardiovasc Drugs Ther 1997; 11: 485-491.
30. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354: 447-455.
31. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, for the Japan EPA lipid intervention study (JELIS) investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolemic patients (JELIS): a randomized open-label, blinded, end-point analysis. Lancet 2007; 369: 1090-1098.
32. Oikawa S. Yokoyama M. Origasa H. Matsuzaki M. Matsuzawa Y. Saito Y. Ishikawa Y. Sasaki J. Hishida H. Itakura H. Kita T. Kitabatake A. Nakaya N. Sakata T. Shimada K. Shirato K, for the Japan EPA lipid intervention study (JELIS) investigators. Suppression effects of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA lipid intervention study (JELIS). Atherosclerosis 2009; 206: 535-539.
33. Tanaka K, Ishikawa Y, Yokoyama M, Origasa H, Matsuzaki M, Saito Y, Matsuzawa Y, Sasaki J, Oikawa S, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K for the Japan EPA lipid intervention study (JELIS) investigators. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: Subanalysis of the JELIS trial. Stroke 2008; 39: 2052-2058. 34
34. Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K for Japan EPA lipid intervention study (JELIS) investigators. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008; 200: 135-140.
35. Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawan Y, Oikawa S, Sasaki J, Hishida H, Itakura I, Kita T, Kitabatake A, Nakaya N, Sakata T. Shimada K, Shirato K, Matsuzawa Y, for Japan EPA lipid intervention study (JELIS) investigators. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease secondary prevention analysis from JELIS. Circ J 2009; 73: 1283-1290.
36. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo controlled trial. Lancet 2008; 372: 1223-1230.
37. Kromhout D, Giltay EJ, Geleijnse JM, for the Alpha-Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010; 363: 2015-2026.
38. Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, Gottwik M, Steinbeck G, Del Castillo U, Sack R, Worth H, Katus H, Spitzer W, Sabin G, Senges J, for the OMEGA Study Group. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010; 122: 2152-2159.
39. Vitamin D and Omega-3 Trial (VITAL). Sponsored by the National Cancer Institute and the National, Heart, Lung, and Blood Institute. Information available at http://www.ClinicalTrials.gov.
40. ASCEND: A study of cardiovascular events in diabetes. Sponsored by the British Heart Foundation. Information available at http://www.ctsu.ox.ac.uk.
41. Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 2006; 47(8S): C19-31.
42. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003; 41(4S): 37S-42S.
43. Luostarinen R, Boberg M, Saldeen T. Fatty acid composition in total phospholipids of human coronary arteries in sudden cardiac death. Atherosclerosis 1993; 99: 187-193.
44. Lemaitre RN, King IB, Raghunathan TE, Pearce RM, Weinmann S, Knopp RH, Copass MK, Cobb LA, Siscovick DS. Cell membrane trans-fatty acids and the risk of primary cardiac arrest. Circulation 2002; 105: 697-701.
45. Geppert J, Kraft V, Demmelmair H, and Koletzko B. Docosahexaenoic acid supplementation in vegetarians effectively increases omega-3 index: a randomized trial. Lipids 2005; 40: 807-814.
46. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002; 21: 495-505.
47. Farzaneh-Far R, Harris W, Garg S, Whooley MA. Inverse association of erythrocyte n-3 fatty acid levels with inflammatory biomarkers in patients with stable coronary artery disease: The Heart and Soul Study. Atherosclerosis 2009; 205: 538-543.
48. He K, Liu K, Daviglus ML, Jenny NS, Mayer-Davis E, Jiang R, Steffen L, Siscovick D, Tsai M, Herrington D. Associations of dietary long-chain n-3 polyunsaturated fatty acids and fish with biomarkers of inflammation and endothelial activation (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol 2009; 103: 1238-1243.
49. Nanni S, Melandri G, Hanemaaijer R, Cervi V, Tomasi L, Altimari A, Van Lent N, Tricoci P, Bacchi L, Branzi A. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms. Transl Res 2007; 149: 137-144.
50. Mehra MR, Lavie CJ, Ventura HO, Milani RV. Fish oils produce anti-inflammatory effects and improve body weight in severe heart failure. J Heart Lung Transplant 2006; 25: 834-838.
51. Ciubotaru I, Lee YS, Wander RC. Dietary fish oil decreases C-reactive protein, interleukin-6, and triacylglycerol to HDL-cholesterol ratio in postmenopausal women on HRT. J Nutr Biochem 2003; 14: 513-521.
52. Knapp HR, Reilly IA, Alessandrini P, FitzGerald GA. In vivo indexes of platelet and vascular function during fish-oil administration in patients with atherosclerosis. N Engl J Med 1986; 314: 937-942.
53. Mori TA, Beilin LJ, Burke V, Morris J, Ritchie J. Interactions between dietary fat, fish, and fish oils and their effects of platelet function in men at risk for cardiovascular disease. Arterioscler Thromb Vasc Biol 1997; 17: 279-286.
54. Gajos G, Rostoff P, Undas A, Piwowarska W. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2010; 55: 1671-1678.
55. Gajos G, Zalewski J, Rostoff P, Nessler J, Piwowarska W, Undus A. Reduced thrombin formation and altered clot properties induced by polyunsaturated omega-3 fatty acids on top on dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA- PCI Clot). Arterioscler Thromb Vasc Biol 2011; available at http://atub.ahajournals.org.
56. Lev EI, Solodky A, Harel N, Mager A, Brosh D, Assali A, Roller M, Battler A, Kleiman NS, Kornowski R. Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation. J Am Coll Cardiol 2010; 55: 114-121.
57. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, Franzosi MG, Geraci E, Levantesi G, Maggioni AP, Mantini L, Marfisi RM, Mastrogiuseppe G, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Tucci C, Valagussa F, GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction. Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105: 1897-1903.
58. Mozaffarian D, Psaty BM, Rimm EB, Lemaitre RN, Burke GL, Lyles MF, Lefkowitz D, Siscovick DS. Fish intake and risk of incident atrial fibrillation. Circulation 2004; 110: 368-373.
59. Calo L, Bianconi L, Colivicchi F, Lamberti F, Loricchi L, de Ruvo E, Meo A, Pandozi C, Staibano M, Santini M. N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery. A randomized, controlled trial. J Am Coll Cardiol. 2005; 45: 1723-1728.
60. Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular disease. J Am Coll Cardiol 2009; 54: 585-594.
61. Anand RG, Alkadri M, Lavie CJ, Milani RV. The role of fish oil in arrhythmia prevention. J Cardiopulm Rehabil 2008; 28:92-98.
62. Raitt MH, Connor WE, Morris C, Kron J, Halperin B, Chugh SS, McClelland J, Cook J, MacMurdy K, Swenson R, Connor SL, Gerhard G, Kraemer DF, Oseran D, Marchant C, Calhoun D, Shnider R, McAnulty J. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA 2005; 293: 2884-2891.
63. Brouwer IA, Zock PL, Camm AJ, Bocker D, Hauer RN, Wever EF, Dullemeijer C, Ronden JE, Katan MB, Lubinski A, Buschler H, Schouten EG, SOFA Study Group. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA 2006; 295: 2613-2619.
64. Leon H, Shibata MC, Sivakumaran S, Dorgan M, Chatterley T, Tsuyuki RT. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ 2008; 337: a2931.
65. Macchia A, Levantesi G, Franzosi MG, Geraci E, Maggioni AP, Marfisi R, Nicolosi GL, Schweiger C, Tavazzi L, Tognoni G, Valagussa F, Marchioli R, GISSIPrevenzione Investigators. Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. Eur J Heart Fail 2005; 7: 904-909.
66. Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA 2010; 304: 2363-2372.
67. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992; 70: 733-737.
68. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97: 1029-1036.
69. Eberly LE, Stamler J, Neaton JD, the Multiple Risk Factor Intervention Trial Research Group. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 2003; 163: 1077-1083.
70. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008; 300: 2142-2152.
71. Faergeman O, Holme I, Fayyad R, Bhatia S, Grundy SM, Kastelein JJ, LaRosa JC, Larsen ML, Lindahl C, Olsson AG, Tikkanen MJ, Waters DD, Pedersen TR, Steering Committees of IDEAL and TNT Trials. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am J Cardiol 2009; 104: 459-463.
72. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt M, Khaw KT, Gudnason V. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115: 450-458.
73. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010; 375: 1634-1639.
74. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
75. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S, American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation published online Apr 18, 2011.
76. Grundy SM, Cleeman JI, Merz NB, Brewer B, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239.
77. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard B, Stein JH, Witztum JL. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008; 31: 811-822.
78. Christian JB, Bourgeois N, Snipes R, Lowe KA. Prevalence of severe (500 to 2,000 mg/dL) hypertriglyceridemia in United States adults. Am J Cardiol 2011; 107: 891-897.
79. Karalis DG, Subramanya RD, Hessen SE, Liu L, Victor MF. Achieving optimal lipid goals in patients with coronary artery disease. Am J Cardiol 2011; 107: 886-890.
80. Harris WS. N-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997; 65(suppl): 1645S-1654S.
81. Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol 2006;98(suppl): 71i-76i.
82. Harris WS, Ginsberg HN, Arunakul N, Shacter NS, Windsor SL, Adams H, Berglund L, Osmundsen K. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 1997; 4: 385-391.
83. Van Dam M, Stalenhoef AH, Wittekoek J, Trip J, Prins MH, Kastelein JJ. Efficacy of concentrated n-3 fatty acids in hypertriglyceridemia. A comparison with gemfibrozil. Clin Drug Invest 2001; 21: 175-178.
84. Minnema MC, Wittekoek ME, Schoonenboom N, Kastelein JJ, Hack CE, ten Cate H. Activation of the contact system of coagulation does not contribute to the hemostatic imbalance in hypertriglcyeridemia. Arterioscler Thromb Vasc Biol 1999; 19: 2548-2553.
85. Stalenhoef AF, de Graaf J, Wittekoek ME, Bredie SJ, Demacker PN, Kastelein JJ. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients wit hypertriglyceridemia. Atherosclerosis 2000; 153: 129-138.
86. Gerber JG, Kitch DW, Fichtenbaum CJ, Zackin RA, Charles S, Hogg E, Acosta EP, Connick E, Wohl D, Kojik EM, Benson CA, Aberg JA, for the AIDS Clinical Trial Group A5186 Team. J Acquir Immune Defic Syndr 2008; 47: 459-466.
87. Durrington PN, Bhatnagar D, Mackness MI, Morgan J, Julier K, Khan MA, France M. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persistant hypertriglyceridemia. Heart 2001; 85: 544-548.
88. Bays HE, Maki KC, McKenney J, Snipes R, Meadowcroft A, Schroyer R, Doyle RT, Stein E. Long-term up to 24-month efficacy and safety of concomitant prescription omega-3 fatty acid ethyl esters and simvastatin in hypertriglyceridemic patients. Curr Med Res Opin 2010; 26: 907-915.
89. Roth EM, Bays HE, Forker AD, Maki KC, Carter R, Doyle RT, Stein EA. Prescription omega-3 fatty acids as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects. J Cardiovasc Pharmacol 2009; 54: 196-203.
90. Isley WL, Miles JM, Harris WS. Pilot study of combined therapy with omega-3 fatty acids and niacin in atherogenic dyslipidemia. J Clin Lipidol 2007; 1: 211-217.
91. Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 1993; 88: 523-533.
92. Appel LJ, Miller ER, Seidler AJ, Whelton PK. Does supplementation of diet with "fish oil" reduce blood pressure? A meta-analysis of controlled clinical trial. Arch Intern Med 1993; 153: 1429-1428.
93. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens 2002; 20: 1493-1499.
94. Yamagishi K, Iso H, Date C, Fukui M, Wakai K, Kikuchi S, Inaba Y, Tanabe N, Tamakoshi A, for the JACC Study Group. Fish, ω-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese: The JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk) study. J Am Coll Cardiol 2008; 52: 988-996.
95. Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, Gheorghiade M, Cas LD. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol 2011; 57: 870-879.
96. Blackburn EH. Switching and signaling at the telomere. Cell 2001; 106: 661-673.
97. Blackburn EH. Structure and function of telomeres. Nature 1991; 350: 569-573.
98. Cawthon RM, Smith KR, O'Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years and older. Lancet 2003; 361: 393-395.
99. Farzaneh-Far R, Cawthon RM, Na B, Browner WS, Schiller NB, Whooley MA. Prognostic value of leukocyte telomere length in patients with stable coronary artery disease: data from the Heart and Soul Study. Arterioscler Thromb Vasc Biol 2008; 28: 1379-1384.
100. Farzaneh-Far R, Lin J, Epel ES, Harris WS, Blackburn EH, Whooley MA. Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease. JAMA 2010; 303: 250-257.
101. Lawson LD, Hughes BG, Absorption of eicosapentaenoic acid and docosahexaenoic acid from fish oil triacylglycerols or fish oil ethyl esters coingested with a high fat meal. Biochem Biophys Res Commu 1988; 156: 960-963.
102. Dyerberg J, Madsen P, Moller JM, Aardestrup I, Schmidt EB. Bioavailability of marine n-3 fatty acid formulations. Prostaglandins Leukotrienes Essent 2010; 83: 137-141.
103. Luley C, Weiland H, Grunwald J. Bioavailability of omega-3 fatty acids: ethylester preparations are as suitable as triglyceride preparations. Akt Ernahr Med 1990; 15: 123-125.
104. Harris WS, Zucker ML, Dujovne CA. Omega-3 fatty acids in hypertriglyceridemic patients: triglcyerides vs. ethyl esters. Am J Clin Nutr 1988; 48: 992-997.
105. Bays H. AMR101: a pure-EPA omega-3 fatty acid lowers triglycerides in patients with very high triglycerides without raising LDL-C: the MARINE study. Presented at the National Lipid Association 2011 Annual Scientific Sessions.
106. The ANCHOR study. Available at http://investor.aramincorp.com/releases.cfm.
107. Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol 2007; 99(suppl): 35C-43C.
108. Hansen JB, Lyngmo V, Svensson B, Nordoy A. Inhibition of exercise-induced shortening of bleeding time by fish oil in familial hypercholesterolemia (type IIa). Arterioscler Thromb Vasc Biol 1993; 13: 98-104.
109. Harris WS. Expert opinion: omega-3 fatty acids and bleeding-cause for concern? Am J Cardiol 2007; 99(suppl): 44C-46C.
110. Eritsland J, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor M. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol 1996; 77: 31-36.
111. Leaf A, Jorgenson MB, Jacobs AK, Cote G, Schoenfield DA, Scheer J, Weiner BH, Slack JD, Kellet MA, Raizner AE, Webner PC, Mahrer PR, Rossouw JE. Do fish oil prevent restenosis after coronary angioplasty? Circulation 1994; 90: 2248-2257.
112. Bender NK, Kraynak MA, Chiquette E, Linn WD, Clark GM, Bussey HI. Effects of marine fish oils on the anticoagulation status of patients receiving chronic warfarin therapy. J Thromb Thrombolysis 1998; 5: 257-258
113. Watson PD, Joy PS, Nkonde C, Hessen SE, Karalis DG. Comparison of bleeding complications with omega-3 fatty acids + aspirin + clopidogrel - versus - aspirin + clopidogrel in patients with cardiovascular disease. Am J Cardiol 2009; 104: 1052-1054.
114. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risk and benefits. JAMA 2006; 296: 1885-1899.
115. Berquin IM, Edwards IJ, Chen YQ. Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Letters 2008; 269: 363-377.
116. Kimura Y, Kono S, Toyomura K, Nagano J, Mizoue T, Moore MA, Mibu R, Tanaka M, Kakeji Y, Maehara Y, Okamura T, Ikejiri K, Futami K, Yasunami Y, Maekawa T, Takenaka K, Ichimiya H, Imaizumi N. Meat, fish, and fat intake in relation to subsitespecific risk of colorectal cancer: the Fukuoka Colorectal Cancer Study. Cancer Sci 2007; 98: 590-597.
117. Theodoraou E, McNeill G, Cetnarskyj R, Farrington SM, Tenesa A, Barnetson R, Porteous M, Dunlop M, Campbell H. Dietary fatty acids and colorectal cancer: a case control study. Am J Epidemiiol 2007; 166: 181-195.
118. Chavarro JE, Stampfer MJ, Li H, Campos H, Kurth T, Ma J. A prospective study of polyunsaturated fatty acid levels in blood and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007; 16: 1364-1370.
119. Ritch CR, Wan RL, Stephens LB, Taxy JB, Huo D, Gong EM, Zagaja GP, Brendler CB. Dietary fatty acids correlate with prostate cancer biopsy grade and volume in Jamaican men. J Urol 2007; 177: 97-101.
120. Brasky TM, Till C, White E, Neuhouser ML, Song X, Goodman P, Thompson IM, King IB, Albanes D, Kristal AR. Serum phospholipid fatty acids and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Am J Epidemiol (2011) first published online April 24, 2011 doi:10.1093/aje/kwr027.